From the publishers of JADPRO

Myelofibrosis Resource Center

Advertisement

Defective neutrophil clearance in JAK2V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24

Last Updated: Thursday, August 21, 2025

Researchers investigated neutrophil homeostasis and cellular interactions in myeloproliferative neoplasms (MPN). Results showed that JAK2V617F neutrophils evade clearance and accumulate in JAK2V617F MPN through upregulation of CD24. The researchers concluded that CD24 may be a candidate innate immune checkpoint in MPN.

Blood
Advertisement
News & Literature Highlights

Nature Communications

Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling

Journal of Inflammation Research

Prognostic implications of red blood cell distribution width to albumin ratio in myelofibrosis: A 10 year multicenter and retrospective study

Clinical Lymphoma, Myeloma & Leukemia

Real-world evidence on outcomes and safety of ropeginterferon alfa-2b in patients with myeloproliferative neoplasms: A retrospective cohort study

International Journal of Hematology

Efficacy and safety of momelotinib in Janus kinase inhibitor experienced Asian patients with myelofibrosis and anemia

Blood

Defective neutrophil clearance in JAK2V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24

Acta Haematologica

Impact of early-onset or worsening anemia in patients with myelofibrosis treated with ruxolitinib: A post hoc analysis of the JUMP studyImpact of early-onset or worsening anemia in patients with myelofibrosis treated with ruxolitinib: A post hoc analysis of the JUMP study

European Journal of Haematology

Time without transfusion reliance (TWiTR): Integrating survival quality into myelofibrosis treatment strategies based on the phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials

Indian Journal of Hematology and Blood Transfusion

Renal impairment in myeloproliferative neoplasms: An under-reported complication

Blood Neoplasia

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response

Blood Work

Primary myelofibrosis involving lymph nodes with the same mutational profile in bone marrow

Advertisement
Advertisement